Wall Street analysts expect that Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will announce ($0.25) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Sunesis Pharmaceuticals’ earnings. Sunesis Pharmaceuticals reported earnings per share of ($0.62) during the same quarter last year, which would indicate a positive year over year growth rate of 59.7%. The company is scheduled to issue its next quarterly earnings report on Thursday, November 2nd.

On average, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($1.66) per share for the current fiscal year, with EPS estimates ranging from ($1.94) to ($1.37). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.42) per share, with EPS estimates ranging from ($1.96) to ($0.87). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.35. During the same period last year, the company earned ($0.12) EPS.

Several research analysts have weighed in on SNSS shares. ValuEngine cut shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Zacks Investment Research cut shares of Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $3.00 price target on shares of Sunesis Pharmaceuticals in a report on Thursday, July 27th.

Sunesis Pharmaceuticals (NASDAQ SNSS) remained flat at $2.21 during midday trading on Thursday. The stock had a trading volume of 42,172 shares. The company has a 50 day moving average price of $2.14 and a 200 day moving average price of $2.82. Sunesis Pharmaceuticals has a 52-week low of $1.84 and a 52-week high of $4.53. The firm’s market capitalization is $51.96 million.

TRADEMARK VIOLATION NOTICE: “-$0.25 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/12/0-25-earnings-per-share-expected-for-sunesis-pharmaceuticals-inc-snss-this-quarter.html.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Balyasny Asset Management LLC bought a new position in shares of Sunesis Pharmaceuticals during the second quarter worth approximately $5,400,000. Vanguard Group Inc. increased its holdings in shares of Sunesis Pharmaceuticals by 4.1% during the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after purchasing an additional 23,819 shares during the period. Sphera Funds Management LTD. increased its holdings in shares of Sunesis Pharmaceuticals by 54.6% during the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 68,212 shares during the period. Neuberger Berman Group LLC increased its holdings in shares of Sunesis Pharmaceuticals by 16.6% during the first quarter. Neuberger Berman Group LLC now owns 140,555 shares of the biopharmaceutical company’s stock worth $576,000 after purchasing an additional 20,000 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of Sunesis Pharmaceuticals by 1.1% during the first quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock worth $458,000 after purchasing an additional 1,230 shares during the period. 57.54% of the stock is currently owned by institutional investors.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.